%0 Journal Article %1 Lee:2013:Gut:22698649 %A Lee, Y C %A Chen, T H %A Chiu, H M %A Shun, C T %A Chiang, H %A Liu, T Y %A Wu, M S %A Lin, J T %D 2013 %J Gut %K gastric_cancer h.pylori prevention %N 5 %P 676-682 %R 10.1136/gutjnl-2012-302240 %T The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention %U http://www.ncbi.nlm.nih.gov/pubmed/22698649?dopt=Abstract %V 62 %X To evaluate the benefit of mass eradication of Helicobacter pylori infection in reducing premalignant gastric lesions.Mass eradication of H pylori infection was started from 2004 for a Taiwanese population with prevalent H pylori infection, who were >30 years of age. Participants positive for the (13)C-urea breath test underwent endoscopic screening and 1-week clarithromycin-based triple therapy. For subjects whose initial treatment failed, 10-day levofloxacin-based triple therapy was administered. The main outcome measures were changes in the prevalence of H pylori infection and premalignant gastric lesions, and changes in the incidence of premalignant gastric lesions and gastric cancer before (1995-2003) and after (2004-2008) chemoprevention using various comparators.The reduction in H pylori infection was 78.7% (95% CI 76.8% to 80.7%), and the estimated incidence of re-infection/recrudescence was 1% (95% CI 0.6% to 1.4%) per person-year. The effectiveness of reducing the incidence of gastric atrophy resulting from chemoprevention was significant at 77.2% (95% CI 72.3% to 81.2%), while the reduction in intestinal metaplasia was not significant. Compared with the 5-year period before chemoprevention and in the absence of endoscopic screening, the effectiveness in reducing gastric cancer incidence during the chemoprevention period was 25% (rate ratio 0.753, 95% CI 0.372 to 1.524). The reduction in peptic ulcer disease was 67.4% (95% CI 52.2% to 77.8%), while the incidence of oesophagitis was 6% (95% CI 5.1% to 6.9%) after treatment.Population-based eradication of H pylori infection has led to a significant reduction in gastric atrophy at the expense of increased oesophagitis. The ultimate benefit in reducing gastric cancer incidence and its mortality should be validated by a further long-term follow-up.NCT00155389.

@article{Lee:2013:Gut:22698649, abstract = {To evaluate the benefit of mass eradication of Helicobacter pylori infection in reducing premalignant gastric lesions.Mass eradication of H pylori infection was started from 2004 for a Taiwanese population with prevalent H pylori infection, who were >30 years of age. Participants positive for the (13)C-urea breath test underwent endoscopic screening and 1-week clarithromycin-based triple therapy. For subjects whose initial treatment failed, 10-day levofloxacin-based triple therapy was administered. The main outcome measures were changes in the prevalence of H pylori infection and premalignant gastric lesions, and changes in the incidence of premalignant gastric lesions and gastric cancer before (1995-2003) and after (2004-2008) chemoprevention using various comparators.The reduction in H pylori infection was 78.7% (95% CI 76.8% to 80.7%), and the estimated incidence of re-infection/recrudescence was 1% (95% CI 0.6% to 1.4%) per person-year. The effectiveness of reducing the incidence of gastric atrophy resulting from chemoprevention was significant at 77.2% (95% CI 72.3% to 81.2%), while the reduction in intestinal metaplasia was not significant. Compared with the 5-year period before chemoprevention and in the absence of endoscopic screening, the effectiveness in reducing gastric cancer incidence during the chemoprevention period was 25% (rate ratio 0.753, 95% CI 0.372 to 1.524). The reduction in peptic ulcer disease was 67.4% (95% CI 52.2% to 77.8%), while the incidence of oesophagitis was 6% (95% CI 5.1% to 6.9%) after treatment.Population-based eradication of H pylori infection has led to a significant reduction in gastric atrophy at the expense of increased oesophagitis. The ultimate benefit in reducing gastric cancer incidence and its mortality should be validated by a further long-term follow-up.NCT00155389.}, added-at = {2013-05-06T17:59:32.000+0200}, author = {Lee, Y C and Chen, T H and Chiu, H M and Shun, C T and Chiang, H and Liu, T Y and Wu, M S and Lin, J T}, biburl = {https://www.bibsonomy.org/bibtex/289e83eb9989610d19b55d07d7370b970/iskanbasal}, description = {The benefit of mass eradication of Helicobacter pylori i... [Gut. 2013] - PubMed - NCBI}, doi = {10.1136/gutjnl-2012-302240}, interhash = {f57bbb8d6ff6b5ef6f62f4e657fe6282}, intrahash = {89e83eb9989610d19b55d07d7370b970}, journal = {Gut}, keywords = {gastric_cancer h.pylori prevention}, month = may, number = 5, pages = {676-682}, pmid = {22698649}, timestamp = {2013-05-06T17:59:32.000+0200}, title = {The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention}, url = {http://www.ncbi.nlm.nih.gov/pubmed/22698649?dopt=Abstract}, volume = 62, year = 2013 }